scholarly article | Q13442814 |
P356 | DOI | 10.1177/1076029612463424 |
P698 | PubMed publication ID | 23104956 |
P50 | author | Michał Myśliwiec | Q29078929 |
Beata Naumnik | Q57541897 | ||
Ewa Koc-Zorawska | Q117216958 | ||
P2093 | author name string | Katarzyna Klejna | |
P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin | Q28295204 | ||
Low-molecular-weight heparin for routine hemodialysis | Q33381414 | ||
Osteoprotegerin ligand: a regulator of immune responses and bone physiology. | Q34079327 | ||
Osteoprotegerin and bone mineral metabolism in renal failure | Q35806269 | ||
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | Q35848843 | ||
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 | ||
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease | Q36686037 | ||
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. | Q37188485 | ||
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response | Q43654531 | ||
PTH differentially regulates expression of RANKL and OPG. | Q43832667 | ||
Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients | Q43904863 | ||
Increased levels of osteoprotegerin in hemodialysis patients | Q44245391 | ||
Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition | Q44745296 | ||
Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation | Q47254973 | ||
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients | Q47422222 | ||
Osteoprotegerin and bone mineral density in hemodialysis patients. | Q50780000 | ||
sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients. | Q51728628 | ||
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. | Q53442889 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 433-441 | |
P577 | publication date | 2012-10-26 | |
P1433 | published in | Clinical and Applied Thrombosis-Hemostasis | Q5133805 |
P1476 | title | Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis | |
P478 | volume | 20 |
Q97530990 | Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: a retrospective cohort study |
Q58129712 | Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants |
Q33442494 | Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. |
Q38775640 | Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity |
Search more.